Advertisement

Annals of Surgical Oncology

, Volume 26, Issue 13, pp 4566–4575 | Cite as

The Achievement of a Sustained Virological Response Either Before or After Hepatectomy Improves the Prognosis of Patients with Primary Hepatitis C Virus-Related Hepatocellular Carcinoma

  • Yukiyasu OkamuraEmail author
  • Teiichi Sugiura
  • Takaaki Ito
  • Yusuke Yamamoto
  • Ryo Ashida
  • Katsuhisa Ohgi
  • Katsuhiko Uesaka
Hepatobiliary Tumors

Abstract

Background

Hepatitis C virus (HCV) infection is a major cause of hepatocellular carcinoma (HCC). Achieving a sustained virological response (SVR) is associated with a reduced risk of recurrence. The recent introduction of direct acting antivirals (DAAs) has resulted in SVR rates of nearly 100% in treated patients. The purpose of the present study was to clarify the outcomes in patients who underwent antiviral therapy and patients without antiviral therapy.

Methods

This retrospective study included 220 patients with primary HCV-related HCC who underwent hepatectomy. An SVR was defined as a serum HCV-RNA titer below the detection sensitivity limit at 6 months after the termination of antiviral therapy. Postoperative antiviral therapy was introduced after confirming that there was no early recurrence.

Results

Eighty-eight patients received antiviral therapy. Among these, 58 patients (66%) obtained an SVR. With the exception of one patient, all patients who received DAAs obtained an SVR. The overall survival rate of the pre-operative SVR group was significantly better than that of the preoperative untreated group (P = 0.045). Moreover, there was no recurrence at 3 years after surgery in the pre-operative SVR group. The achievement of an SVR was an independent predictor of overall survival [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.59–0.94, P = 0.011] and recurrence (HR 0.61, 95% CI 0.40–0.94, P = 0.024).

Conclusions

Obtaining an SVR either before or after surgery was associated with the suppression of HCC recurrence after hepatectomy in patients with primary HCV-related HCC.

Notes

Financial Support

There are no grants or other financial support for this study.

Disclosure

The authors declare that there have no conflicts of interest.

References

  1. 1.
    Vital statistics, Ministry of Health, Labour and Welfare. http://www.mhlw.go.jp/english/database/db-hw/vs01.html. Accessed 25 Sep 2017.
  2. 2.
    Kudo M, Izumi N, Sakamoto M, et al. Liver Cancer Study Group of Japan. Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. Liver Cancer. 2016;5:190–7.Google Scholar
  3. 3.
    Shim JH, Jun MJ, Han S, et al. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg. 2015;261:939–46.CrossRefGoogle Scholar
  4. 4.
    Chapman WC, Klintmalm G, Hemming A, et al. Surgical treatment of hepatocellular carcinoma in North America: can hepatic resection still be justified? J Am Coll Surg. 2015;220:628–37.CrossRefGoogle Scholar
  5. 5.
    Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O. Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology. 1999;29:1446–52.CrossRefGoogle Scholar
  6. 6.
    Yasui M, Harada A, Nonami T, et al. Potentially multicentric hepatocellular carcinoma: clinicopathologic characteristics and postoperative prognosis. World J Surg. 1997;21:860–4.CrossRefGoogle Scholar
  7. 7.
    Matsuda M, Fujii H, Kono H, Matsumoto Y. Surgical treatment of recurrent hepatocellular carcinoma based on the mode of recurrence: repeat hepatic resection or ablation are good choices for patients with recurrent multicentric cancer. J Hepatobiliary Pancreat Surg. 2001;8:353–9.CrossRefGoogle Scholar
  8. 8.
    Arii S, Monden K, Niwano M, et al. Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg. 1998;5:86–92.CrossRefGoogle Scholar
  9. 9.
    Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200–7.CrossRefGoogle Scholar
  10. 10.
    Mazzaferro V, Romito R, Schiavo M, et al. HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006;44:1543–54.Google Scholar
  11. 11.
    Shinkawa H, Hasegawa K, Arita J, et al. Impact of sustained virological response to interferon therapy on recurrence of hepatitis C virus-related hepatocellular carcinoma. Ann Surg Oncol. 2017;24:3196–202.CrossRefGoogle Scholar
  12. 12.
    Koda M, Tanaka S, Takemura S, et al. Long-term prognostic factors after hepatic resection for hepatitis C virus-related hepatocellular carcinoma, with a special reference to viral status. Liver Cancer. 2018;7:261–76.CrossRefGoogle Scholar
  13. 13.
    Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–33.CrossRefGoogle Scholar
  14. 14.
    Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.CrossRefGoogle Scholar
  15. 15.
    Kozbial K, Moser S, Schwarzer R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free directacting antiviral treatment. J Hepatol. 2016;65:856–8.CrossRefGoogle Scholar
  16. 16.
    Cardoso H, Vale AM, Rodrigues S, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. J Hepatol. 2016;65:1070–1.CrossRefGoogle Scholar
  17. 17.
    ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CirVir and CO23 CUPILT cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol. 2016;65:734–40.Google Scholar
  18. 18.
    Torres HA, Vauthey JN, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with directacting antivirals: first, do no harm by withdrawing treatment. J Hepatol. 2016;65:862–4.CrossRefGoogle Scholar
  19. 19.
    Minami T, Tateishi R, Nakagomi R, et al. The impact of directacting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. J Hepatol. 2016;65:1272–3.CrossRefGoogle Scholar
  20. 20.
    Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646–9.CrossRefGoogle Scholar
  21. 21.
    Liver Cancer Study Group of Japan General rules for the clinical and pathological study of primary liver cancer, 2008. 5th Japanese ed. Tokyo: Kanehara; 2008.Google Scholar
  22. 22.
    Sobin LH, Gospodarowicz MK, Wittekind CH, editors. TNM Classification of Malignant Tumours, 7th ed. New York: Wiley-Liss; 2009.Google Scholar
  23. 23.
    Okamura Y, Ito T, Sugiura T, Mori K, Uesaka K. Anatomic versus nonanatomic hepatectomy for a solitary hepatocellular carcinoma: a case-controlled study with propensity score matching. J Gastrointest Surg. 2014;18:1994–2002.CrossRefGoogle Scholar
  24. 24.
    Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12:351–5.CrossRefGoogle Scholar
  25. 25.
    Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997;25:87–92.CrossRefGoogle Scholar
  26. 26.
    Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000;89:500–7.CrossRefGoogle Scholar
  27. 27.
    Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor: a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000;32:228–32.CrossRefGoogle Scholar
  28. 28.
    Ikeda K, Kawamura Y, Kobayashi M, et al. Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci. 2017;62:2932–42.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Yukiyasu Okamura
    • 1
    Email author
  • Teiichi Sugiura
    • 1
  • Takaaki Ito
    • 1
  • Yusuke Yamamoto
    • 1
  • Ryo Ashida
    • 1
  • Katsuhisa Ohgi
    • 1
  • Katsuhiko Uesaka
    • 1
  1. 1.Division of Hepato-Biliary-Pancreatic SurgeryShizuoka Cancer Center HospitalSunto-NagaizumiJapan

Personalised recommendations